Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is on recovery track with 22.96% gain from a 1-year low price of $3.92. The company lost -5.68% to attain the price of $4.82 on 4/17/2019. Throughout the recent session, the prices were hovering between $4.71 and $5.1646. These shares are 199.59% off its target price of $14.44 and the current market capitalization stands at $303.85M. The recent change has given its price a -19.42% deficit over SMA 50 and -77.8% deficit over its 52-week high. The stock witnessed -9.91% declines, -51.02% declines and -61.81% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found KPTI’s volatility during a week at 5.17% and during a month it has been found around 5.61%.Karyopharm Therapeutics Inc. (KPTI) Top Holders
Institutional investors currently hold around $263 million or 93% in KPTI stock. Look at its top three institutional owners: Wellington Management Group Llp owns $41.99 million in Karyopharm Therapeutics Inc., which represents roughly 13.82% of the company’s market cap and approximately 15.97% of the institutional ownership. Similar statistics are true for the second largest owner, Consonance Capital Management Lp, which owns 4,810,078 shares of the stock are valued at $24.58 million. The third largest holder is Palo Alto Investors Lp, which currently holds $23.94 million worth of this stock and that ownership represents nearly 7.88% of its market capitalization.
At the end of December reporting period, 62 institutional holders increased their position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by some 10,820,775 shares, 53 decreased positions by 2,830,283 and 18 held positions by 37,869,703. That puts total institutional holdings at 51,520,761 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 4,525,060 shares while 17 institutional investors sold out their entire positions totaling 247,271 shares.Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Insider Trades
Multiple company employees have indulged in significant insider trading. Karyopharm Therapeutics Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Chione Ltd has sold 149,624 shares of Karyopharm Therapeutics Inc. (KPTI) in the trading session dated Feb. 28, 2019. These shares are worth $619,443 and were traded at $4.14 each. The SEC filing shows that Chione Ltd performed a sale of 1,481,643 shares. The 10% Owner disposed these shares by way of transaction on Feb. 27, 2019. The company’s shares were given away at $4.81 per share worth to an income of some $7,126,703 to the account of Chione Ltd.
CEO, Kauffman Michael, sold 12,500 common shares of Karyopharm Therapeutics Inc. (KPTI) in the open market. In a transaction dated Jan. 07, 2019, the shares were put up for sale at an average price of $10.23, raking in a sum of $127,875. After this sale, 1,320,271 common shares of KPTI are directly owned by the insider, with total stake valued at $6,363,706.
In the transaction dated Jan. 07, 2019, a great number of shares sold came courtesy the President & CSO; Shacham Sharon disposed a total of 12,500 shares at an average price of $10.23, amounting to approximately $127,875. The insider now directly owns 1,320,271 shares worth $6,363,706.
Several analysts have released their opinion on Karyopharm Therapeutics Inc. (NASDAQ:KPTI), with 5 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 3 buy, 1 sell and 0 strong sell ratings, collectively assigning a 1.8 average brokerage recommendation [T1].